Our study shows that BAT immunotherapy increases TIL, mediates anti-tumor cytotoxicity, and induces endogenous anti-tumor immunity, which, when combined with targeted treatment with tumor necrosis factor superfamily member LIGHT, further enhances anti-tumor immune responses in this otherwise “cold” tumor histology. This evidence concerns the gene TNFSF14 and neoplasm.